Keytruda

MSD withdraws Keytruda’s US indication for small cell lung cancer

Keytruda failed to meet this requirement in the KEYNOTE-604 trial, as announced in January 2020. ... Keytruda remains a foundational treatment for certain patients with metastatic non-small cell lung cancer.

Sanofi, Regeneron’s Libtayo scores first-line NSCLC approval in the US

In its new NSCLC setting, Libtayo will take on Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab). ... Keytruda has become the new standard-of-care treatment for newly-diagnosed advanced NSCLC, after first winning approval in

AZ withdraws Imfinzi in the US for advanced bladder cancer after post-marketing study fail

NMIBC). A number of immunotherapies are approved for bladder cancer, including Merck &Co/MSD’s Keytruda (pembrolizumab) which became the first checkpoint inhibitor to be approved in the US for NMIBC

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

The overall response rate (ORR) for Keytruda plus Lenvima-treated patients was 71% compared to 36.1% in the Sutent group. ... In this trial, Keytruda plus Lenvima demonstrated superior efficacy benefits compared with Sutent.

BMS and Exelixis’ Opdivo/Cabometyx shows continued benefit in kidney cancer

Both Opdivo combinations will compete with Merck &Co/MSD’s blockbuster checkpoint inhibitor Keytruda (pembrolizumab) plus Pfizer’s TKI Inlyta (axitinib), after the combination treatment received FDA approval in the same ... Topline results from the

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]